04.26.04



## Express Mail No. EV405281365US

INFORMATION
DISCLOSURE STATEMENT

Attorney Docket TECH-004

First Named Inventor TAKAHATA, KYOYA

Application Number 10/634,641

Confirmation No. 7194

Filing Date August 4, 2003

Group Art Unit 1614

Examiner Name N/A

Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

"ANTI-TUMOR PHARMACEUTICAL

COMPOSITION COMPRISING N-VANILLYL

FATTY ACID AMIDE"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

Title:

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. TECH-004 may be charged thereon.

By:

Respectfully submitted,

**BOZICEVIC, FIELD & FRANCIS LLP** 

Date: April 22, 2004

Carol L. Francis

Registration No /36,513

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025 Telephone: (650) 327-3400

Facsimile: (650) 327-3231

PTO/SB/08a (05-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
All Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute	ubstitute for form 1449A/PTO			Complete if Known	
	10 ± 10 ± 10 ± 10 ± 10 ± 10 ± 10 ± 10 ±			Application Number	10/634,641
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	August 4, 2003
				First Named Inventor	TAKAHATA, KYOYA
				Art Unit	1614
	(use as many sheets as necessary)			Examiner Name	N/A
Sheet	1	of	1	Attorney Docket Number	TECH-004

U.S. PATENT DOCUMENTS						
Examiner Initials'	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Cite	Cite	Foreign Patent Document	Publication Date	Name of Batastas as	Pages, Columns, Lines,	
Initials' No.1		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵

	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the		
IIIIIais I	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²	
		MORRE et al. "Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture" <i>Proc. Nat;. Acad. Sci.USA</i> Vol. 92, pp. 1831-1835, March 1995		
		TAKAHATA et al. "Growth Inhibition of capsaicin on hela cells is not mediated by intracellular calcium mobilization" <i>Life Sciences</i> , Vol. 64, No. 13, pp. PL 165-171 (1999)		
		SZALLASI et al. "Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor" <i>LifeSciences</i> Vol. 47, pp. 1399-1408 (1990)		
		MORRE et al. "Capsaicin inhibits plasma membrane NADH oxidase and growth of human and mouse melanoma lines" <i>European Journal of Cancer</i> , Vol. 32A, No. 11, pp. 1995-2003, (1996)		

Examiner	Date
Signature	Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.